Published October 2021 | Version v1
Journal article

Apelin receptor homodimer inhibits apoptosis in vascular dementia

  • 1. School of Basic Medical Sciences, Weifang Medical University, Weifang, 261053 (China)
  • 2. Department of Psychiatry, Shouguang Mental Health Center, Weifang, 261053 (China)
  • 3. Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, CV4 7AL (United Kingdom)
  • 4. Institute of Neurobiology, Jining Medical University, Rizhao, 276800 (China)

Description

Apelin receptor (APJ), a member of family A of the G protein-coupled receptors (GPCRs), is a potential pharmaceutical target for diseases of the nervous system. Our previous work revealed that human APJ can form a homodimer that has different functional characteristics than the monomer. To investigate the effects of APJ homodimers on neuroprotection in vascular dementia (VD), we established VD model in rats and treated the animals by injecting apelin-13 into the lateral ventricle. In addition, we established an oxygen–glucose deprivation/reoxygenation (OGD/R) model in SH-SY5Y cells treated with apelin-13. After apelin-13 stimulation in the VD rat, the level of APJ and APJ homodimer were elevated. Furthermore, APJ homodimer decreased the level of cleaved caspase-3 and cleaved caspase-9 via the Gαi3 and Gαq signaling pathway, thereby increasing the number of neurons and inhibiting apoptosis. Consequently, APJ homodimers may serve as a unique mechanism for neuroprotection against VD and provide new pharmaceutical targets for VD.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.yexcr.2021.112739

Additional details

Identifiers

DOI
10.1016/j.yexcr.2021.112739;
PII
S0014482721002925;

Publishing Information

Journal Title
Experimental Cell Research
Journal Volume
407
Journal Issue
1
Journal Page Range
vp.
ISSN
0014-4827
CODEN
ECREAL

Optional Information

Copyright
Copyright (c) 2021 The Author(s). Published by Elsevier Inc.